估算美国在芬太尼、海洛因和处方阿片类药物流行中纳洛酮的需求:一项建模研究
该建模研究基于12个代表性州的数据,估计2017年美国在芬太尼、海洛因和处方阿片类药物流行下,通过社区项目、提供者处方和药房发起的三个纳洛酮获取点,需多少纳洛酮试剂盒才能使至少80%的目击阿片类药物过量事件中使用纳洛酮。结果显示芬太尼流行的州纳洛酮使用概率最高(58-76%),处方阿片类药物为主的州最低(0-20%);社区和药房获取点比提供者处方有更高的使用概率和每10万人避免死亡数。仅亚利桑那州有足够试剂盒达标,需大幅扩大纳洛酮分布。
要点
- 芬太尼流行州目击过量事件中纳洛酮使用概率为58-76%,处方阿片类为主的州为0-20%。
- 社区和药房发起的纳洛酮获取点比提供者处方有更高的使用概率和每10万人避免死亡数。
- 为达80%目击过量使用纳洛酮,12个建模州每年每10万人需额外0至1270个试剂盒。
核心结论
- 阿片类药物流行类型和纳洛酮获取方式对需分发的试剂盒数量、纳洛酮使用概率和避免的过量死亡数有很大影响。
- 纳洛酮分发范围,尤其是通过社区项目和药房发起的获取点,在几乎每个美国州都值得大幅扩大。
研究设计与样本
- 建模研究,开发并参数化阿片类药物过量风险的机制模型,使用文献综述和改良德尔菲小组定义参数。
- 模型通过整合非法药物供应毒性和纳洛酮获取点的变化进行细化,并利用专有数据源、州卫生部门和全国调查数据对12个代表性美国州2017年数据进行校准。
- 使用反事实建模预测增加纳洛酮分发对避免阿片类药物过量死亡数和所需试剂盒数的影响。
主要发现
- 芬太尼流行的三个建模州目击过量事件中纳洛酮使用概率范围为58-76%,处方阿片类药物为主的州范围为0-20%。
- 2017年州特异性结果中,社区和药房发起的纳洛酮获取点比仅提供者处方有更高的目击过量中纳洛酮使用概率和每10万人避免死亡数。
- 为实现80%目击过量中使用纳洛酮的目标,12个建模州每年每10万人所需额外试剂盒从0(估计已足够)到1270个不等。
- 2017年仅有亚利桑那州有足够试剂盒达到该目标。
关键数值与推荐
- 目标为至少80%的目击阿片类药物过量事件中使用纳洛酮。
- 芬太尼流行州纳洛酮使用概率58-76%,处方阿片类为主州0-20%。
- 12个建模州每年每10万人需额外0至1270个试剂盒以达到80%使用目标。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The US overdose crisis is driven by fentanyl, heroin, and prescription opioids. One evidence-based policy response has been to broaden naloxone distribution, but how much naloxone a community would need to reduce the incidence of fatal overdose is unclear. We aimed to estimate state-level US naloxone need in 2017 across three main naloxone access points (community-based programmes, provider prescription, and pharmacy-initiated distribution) and by dominant opioid epidemic type (fentanyl, heroin, and prescription opioid). METHODS: In this modelling study, we developed, parameterised, and applied a mechanistic model of risk of opioid overdose and used it to estimate the expected reduction in opioid overdose mortality after deployment of a given number of two-dose naloxone kits. We performed a literature review and used a modified-Delphi panel to inform parameter definitions. We refined an established model of the population at risk of overdose by incorporating changes in the toxicity of the illicit drug supply and in the naloxone access point, then calibrated the model to 2017 using data obtained from proprietary data sources, state health departments, and national surveys for 12 US states that were representative of each epidemic type. We used counterfactual modelling to project the effect of increased naloxone distribution on the estimated number of opioid overdose deaths averted with naloxone and the number of naloxone kits needed to be available for at least 80% of witnessed opioid overdoses, by US state and access point. FINDINGS: Need for naloxone differed by epidemic type, with fentanyl epidemics having the consistently highest probability of naloxone use during witnessed overdose events (range 58-76% across the three modelled states in this category) and prescription opioid-dominated epidemics having the lowest (range 0-20%). Overall, in 2017, community-based and pharmacy-initiated naloxone access points had higher probability of naloxone use in witnessed overdose and higher numbers of deaths averted per 100 000 people in state-specific results with these two access points than with provider-prescribed access only. To achieve a target of naloxone use in 80% of witnessed overdoses, need varied from no additional kits (estimated as sufficient) to 1270 kits needed per 100 000 population across the 12 modelled states annually. In 2017, only Arizona had sufficient kits to meet this target. INTERPRETATION: Opioid epidemic type and how naloxone is accessed have large effects on the number of naloxone kits that need to be distributed, the probability of naloxone use, and the number of deaths due to overdose averted. The extent of naloxone distribution, especially through community-based programmes and pharmacy-initiated access points, warrants substantial expansion in nearly every US state. FUNDING: National Institute of Health, National Institute on Drug Abuse.
引用
- Irvine MA, Oller D, Boggis J, et al. Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study. Lancet Public Health. 2022. PMID: 35151372. doi:10.1016/S2468-2667(21)00304-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。